Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Surgery Partners ( (SGRY) ) is now available.
On August 4, 2025, Wayne S. DeVeydt resigned as a director and the Executive Chairman of the Board of Directors of Surgery Partners, Inc., with no disagreements cited regarding company operations, policies, or practices. Following his resignation, Blair E. Hendrix was appointed as Chairman, and the Board’s size was reduced from 11 to 10 directors.
The most recent analyst rating on (SGRY) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Surgery Partners stock, see the SGRY Stock Forecast page.
Spark’s Take on SGRY Stock
According to Spark, TipRanks’ AI Analyst, SGRY is a Neutral.
Surgery Partners’ stock score reflects a mixed financial performance, with strengths in revenue growth offset by profitability challenges and high leverage. The earnings call and decision to remain independent highlight positive strategic directions, yet technical indicators and valuation metrics point to ongoing risks. The company’s future success hinges on improving profitability and managing debt effectively.
To see Spark’s full report on SGRY stock, click here.
More about Surgery Partners
Average Trading Volume: 1,655,278
Technical Sentiment Signal: Sell
Current Market Cap: $2.84B
For a thorough assessment of SGRY stock, go to TipRanks’ Stock Analysis page.